Colorado Cancer Blogs
  • Home
  • Topics
    • Latest News
    • Research
    • Patient Care
    • Philanthropy
    • C3 Magazine
    • Honors
  • Cancer Types
    • bladder cancer
    • blood cancer
    • brain cancer
    • breast cancer
    • colorectal cancer
    • gynecologic cancer
    • head & neck cancer
    • lung cancer
    • pancreatic cancer
    • pediatric cancer
    • prostate cancer
    • sarcoma
    • skin cancer
Select Page
Research symbiosis makes mathematical crystal ball to gaze into future of prostate cancer treatment

Research symbiosis makes mathematical crystal ball to gaze into future of prostate cancer treatment

by Garth Sundem | Aug 4, 2017 | Latest News, Research

The chemotherapy docetaxel is widely accepted as a standard therapy for metastatic castration-resistant prostate cancer. But 10-20 percent of patients will have adverse side effects that force discontinuation of treatment. These patients may have been better off with...
Study evaluates overall geriatric health during androgen deprivation therapy

Study evaluates overall geriatric health during androgen deprivation therapy

by Garth Sundem | Jun 5, 2017 | Latest News, Research

Androgen drives many prostate cancers. But the body uses androgen for muscle growth and maintenance, among other functions. An ongoing study published in the Journal of Clinical Oncology along with the American Society for Clinical Oncology (ASCO) Annual Meeting 2017...
New clinical trial framework tests ‘natural’ cures for cancer

New clinical trial framework tests ‘natural’ cures for cancer

by Garth Sundem | May 16, 2017 | Featured, Latest News

A University of Colorado Cancer Center clinical trial is now recruiting prostate cancer patients who would otherwise be on a watch-and-wait protocol to test the ability of grape seed extract to slow the rise of prostate-specific antigen (PSA), a common marker of...
Breakthrough study stops fat-eating prostate cancer cells

Breakthrough study stops fat-eating prostate cancer cells

by Taylor Abarca | May 3, 2017 | Research

Patients with castration resistant prostate cancer (CRPC) usually have a poor prognosis. In part, this is due to the cancer’s ability to resist anti-androgen therapy. A University of Colorado Cancer Center study published today in Oncotarget shows that combining a...
Trial shows responses to abiraterone acetate in some prostate cancer patients with initial hormone induction failure

Trial shows responses to abiraterone acetate in some prostate cancer patients with initial hormone induction failure

by Garth Sundem | Apr 5, 2017 | Latest News, Research

Patients with metastatic prostate cancer whose PSA levels remain high despite initial hormone treatments have historically had poor prognosis, with survival typically in the 1-2 year range. Results of a 40-person clinical trial published in JAMA Oncology show that 13...
« Older Entries
Next Entries »

Colorado Cancer Blogs

  • About Us
  • Comment Policy
  • Cover My News!

CU Cancer Center

  • Find a Doctor
  • Clinical Trials
  • Remote Second Opinion
  • Events

Subscribe to CU Cancer Blogs via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

  • Facebook
  • Twitter
  • Instagram

Copyright © 2021 Colorado Cancer Blogs